Clinical benefits of non‐taxane chemotherapies in unselected patients with symptomatic metastatic castration‐resistant prostate cancer after docetaxel: the GETUG‐P02 study

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|115|1|65-73

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.115, Iss.1, 2015-01, pp. : 65-73

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

By  

Oncology, Vol. 92, Iss. 2, 2016-12 ,pp. : 94-100

Karger

Access to resources Recommend Favorite

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 250-256

John Wiley & Sons Inc

Access to resources Recommend Favorite

Docetaxel rechallenge after an initial good response in patients with metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 115, Iss. 5, 2015-05 ,pp. : 744-752

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite